184 related articles for article (PubMed ID: 27013085)
21. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone.
Berg G; Lindstedt G; Suurküla M; Jansson S
J Endocrinol Invest; 2002 Jan; 25(1):44-52. PubMed ID: 11883865
[TBL] [Abstract][Full Text] [Related]
22. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study.
Pacini F; Ladenson PW; Schlumberger M; Driedger A; Luster M; Kloos RT; Sherman S; Haugen B; Corone C; Molinaro E; Elisei R; Ceccarelli C; Pinchera A; Wahl RL; Leboulleux S; Ricard M; Yoo J; Busaidy NL; Delpassand E; Hanscheid H; Felbinger R; Lassmann M; Reiners C
J Clin Endocrinol Metab; 2006 Mar; 91(3):926-32. PubMed ID: 16384850
[TBL] [Abstract][Full Text] [Related]
23. Treatment room length-of-stay and patient throughput with radioiodine thyroid remnant ablation in differentiated thyroid cancer: comparison of thyroid-stimulating hormone stimulation methods.
Vallejo Casas JA; Mena Bares LM; Gálvez MA; Marlowe RJ; Latre Romero JM; Martínez-Paredes M
Nucl Med Commun; 2011 Sep; 32(9):840-6. PubMed ID: 21691237
[TBL] [Abstract][Full Text] [Related]
24. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer.
Mariani G; Ferdeghini M; Augeri C; Villa G; Taddei GZ; Scopinaro G; Boni G; Bodei L; Rabitti C; Molinari E; Bianchi R
Cancer Biother Radiopharm; 2000 Apr; 15(2):211-7. PubMed ID: 10803328
[TBL] [Abstract][Full Text] [Related]
25. [Recombinant human TSH stimulation in radioiodine treatment of disseminated differentiated thyroid cancer--update of current and our own experiences].
Hasse-Lazar K; Handkiewicz-Junak D; Roskosz J; Szpak-Ulczok S; Krajewska J; Jurecka-Lubieniecka B; Jarzab B
Endokrynol Pol; 2006; 57(4):445-50. PubMed ID: 17006851
[TBL] [Abstract][Full Text] [Related]
26. Comparison between remnant and red-marrow absorbed dose in thyroid cancer patients submitted to 131I ablative therapy after rh-TSH stimulation versus hypothyroidism induced by L-thyroxine withdrawal.
Vaiano A; Claudio Traino A; Boni G; Grosso M; Lazzeri P; Colato C; Davì MV; Francia G; Lazzeri M; Mariani G; Ferdeghini M
Nucl Med Commun; 2007 Mar; 28(3):215-23. PubMed ID: 17264781
[TBL] [Abstract][Full Text] [Related]
27. Usefulness of recombinant human TSH aided radioiodine doses administered in patients with differentiated thyroid carcinoma.
Pitoia F; Tamer EE; Schere DB; Passerieu M; Bruno OD; Niepomniszcze H
Medicina (B Aires); 2006; 66(2):125-30. PubMed ID: 16715760
[TBL] [Abstract][Full Text] [Related]
28. Effect of recombinant human TSH on the uptake of radioactive iodine ((123)I) by the thyroid gland in healthy beagles.
Campos M; Peremans K; Duchateau L; Dobbeleir A; Vandermeulen E; van Hoek I; Paes G; Daminet S
Domest Anim Endocrinol; 2010 Nov; 39(4):215-21. PubMed ID: 20688462
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study).
Meier CA; Braverman LE; Ebner SA; Veronikis I; Daniels GH; Ross DS; Deraska DJ; Davies TF; Valentine M; DeGroot LJ
J Clin Endocrinol Metab; 1994 Jan; 78(1):188-96. PubMed ID: 8288703
[TBL] [Abstract][Full Text] [Related]
30. Radioiodine 131I treatment for large nodular goiter: recombinant human thyrotropin allows the reduction of radioiodine 131I activity to be administered in patients with low uptake.
Ceccarelli C; Antonangeli L; Brozzi F; Bianchi F; Tonacchera M; Santini P; Mazzeo S; Bencivelli W; Pinchera A; Vitti P
Thyroid; 2011 Jul; 21(7):759-64. PubMed ID: 21568727
[TBL] [Abstract][Full Text] [Related]
31. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration.
Luster M; Felbinger R; Dietlein M; Reiners C
Thyroid; 2005 Oct; 15(10):1147-55. PubMed ID: 16279848
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the cytogenetic effects of (131)I preceded by recombinant human thyrotropin (rhTSH) in peripheral lymphocytes of Wistar rats.
da Silva MA; Calil Cury Guimarães MI; Yoriyaz H; Carvalho Pinto Ribela MT; Buchpiguel CA; Bartolini P; Okazaki K
Radiat Environ Biophys; 2008 Nov; 47(4):453-61. PubMed ID: 18712404
[TBL] [Abstract][Full Text] [Related]
33. Recombinant human thyrotropin versus thyroid hormone withdrawal in radioiodine remnant ablation for differentiated thyroid cancer: a meta-analysis.
Fu H; Ma C; Tang L; Wu F; Liu B; Wang H
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):121-8. PubMed ID: 24844252
[TBL] [Abstract][Full Text] [Related]
34. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
[TBL] [Abstract][Full Text] [Related]
35. Analysis of Short-Term and Stable DNA Damage in Patients with Differentiated Thyroid Cancer Treated with
Signore A; Campagna G; Marinaccio J; Vitis M; Lauri C; Berardinelli F; Tofani A; Chianelli M; Borro M; Gentile G; Simmaco M; Colombini F; Giovanetti A; Sgura A
J Nucl Med; 2022 Oct; 63(10):1515-1522. PubMed ID: 35115370
[TBL] [Abstract][Full Text] [Related]
36. rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of (131)I.
Menzel C; Kranert WT; Döbert N; Diehl M; Fietz T; Hamscho N; Berner U; Grünwald F
J Nucl Med; 2003 Jul; 44(7):1065-8. PubMed ID: 12843221
[TBL] [Abstract][Full Text] [Related]
37. Short-term hypothyroidism in thyroid cancer patients and cognitive-motor performance relevant for driving.
Lodemann E; Bockisch A; Görges R
Psychoneuroendocrinology; 2012 Oct; 37(10):1726-35. PubMed ID: 22541716
[TBL] [Abstract][Full Text] [Related]
38. Cytotoxic and genotoxic effects of
Valgôde FGS; da Silva MA; Vieira DP; Ribela MTCP; Bartolini P; Okazaki K
Environ Mol Mutagen; 2017 Jul; 58(6):451-461. PubMed ID: 28561379
[TBL] [Abstract][Full Text] [Related]
39. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.
Mallick U; Harmer C; Yap B; Wadsley J; Clarke S; Moss L; Nicol A; Clark PM; Farnell K; McCready R; Smellie J; Franklyn JA; John R; Nutting CM; Newbold K; Lemon C; Gerrard G; Abdel-Hamid A; Hardman J; Macias E; Roques T; Whitaker S; Vijayan R; Alvarez P; Beare S; Forsyth S; Kadalayil L; Hackshaw A
N Engl J Med; 2012 May; 366(18):1674-85. PubMed ID: 22551128
[TBL] [Abstract][Full Text] [Related]
40. [Cytogenetic study of thyroid patients treated with external irradiation or radioiodine].
Katz N; Esik O; Füzy M; Gundy S
Orv Hetil; 1998 Jun; 139(25):1521-6. PubMed ID: 9676113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
